The increased mortality risk of patients with MetS could be associated with the enhanced expression of ACE2, IL6, and TNF- α adipose tissue secretion and elevated concentration of von Willebrand factor and plasminogen activator inhibitor-163. The gene discussed is VWF; the disease is metabolic syndrome.